2022
Molecular cancer therapeutics

Nonclinical efficacy and safety of CX-2029, an anti-CD71 probody–drug conjugate

View Publication
Details

Authors:
Shweta Singhal, Olga Vasiljeva, et al.
Title of the Article:
Nonclinical efficacy and safety of CX-2029, an anti-CD71 probody–drug conjugate
Journal:
Molecular cancer therapeutics
Year of Publication:
2022
Pages:
1326-1-1336
Volume and Issue Number:
vol. 21, no. 8
ISSN Number:
1538-8514
DOI (Digital Object Identifier):
10.1158/1535-7163.MCT-21-0193
COBISS ID:
116988419
COBISS
Download PDF
Researchers

Researchers

Meet our dedicated researchers behind this publication:

Olga Vasiljeva

References

References & Citations

Upload File Icon - Laboratory X Webflow Template

Access paper

Access the PDF publication document.

Download PDF
More documentation

Related publications

Browse all publications
2016
2016
Biochimie

In vivo imaging of protease activity by Probody therapeutic activation

Olga Vasiljeva

10.1016/j.biochi.2015.11.003

Learn more
2017
2017
Theranostics

Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly selective inhibitory DARPin

Dr. Janja Završnik; Dušan Turk; Olga Vasiljeva; Prof Vito Turk 44bff; Prof. Vito Turk; Boris Turk

10.7150/thno.19081

Learn more
2017
2017
Oncotarget

Cystatin C deficiency suppresses tumor growth in a breast cancer model through decreased proliferation of tumor cells

Dr. Janja Završnik; Dr. Miha Butinar; Mojca Trstenjak Prebanda; Aleksander Krajnc; Robert Vidmar; Marko Fonović; Prof Vito Turk 44bff; Prof. Vito Turk; Boris Turk; Olga Vasiljeva

10.18632/oncotarget.17379

Learn more

Explore our collection of 200+ Premium Webflow Templates